Zong-Wan Mao Selected Research

Small Interfering RNA (siRNA)

10/2022	Ru(II)-modified TiO2 nanoparticles for hypoxia-adaptive photo-immunotherapy of oral squamous cell carcinoma.
4/2017	Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles.
11/2016	Nanoparticle delivery systems for siRNA-based therapeutics.
10/2015	Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
1/2015	Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
1/2014	Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics.
11/2013	High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.
1/2013	Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
3/2012	Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zong-Wan Mao Research Topics

Disease

82	Neoplasms (Cancer) 11/2023 - 04/2011
7	Hypoxia (Hypoxemia) 12/2022 - 10/2020
6	Carcinoma (Carcinomatosis) 10/2023 - 01/2015
6	Triple Negative Breast Neoplasms 12/2022 - 10/2015
6	Neoplasm Metastasis (Metastasis) 04/2022 - 12/2017
5	Phototoxic Dermatitis (Phototoxicity) 01/2022 - 10/2015
5	Mitochondrial Diseases (Mitochondrial Disease) 09/2020 - 02/2012
3	Lung Neoplasms (Lung Cancer) 01/2018 - 04/2015
2	Bites and Stings (Sting) 06/2023 - 10/2022
2	Photosensitivity Disorders (Photodermatitis) 01/2022 - 01/2021
2	Infections 01/2022 - 03/2021
2	COVID-19 01/2022 - 11/2021
2	Body Weight (Weight, Body) 01/2018 - 11/2013
1	Bacterial Infections (Bacterial Infection) 01/2023
1	Carcinogenesis 10/2022
1	Squamous Cell Carcinoma of Head and Neck 10/2022
1	Communicable Diseases (Infectious Diseases) 04/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Wound Infection (Wound Infections) 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2020

Drug/Important Bio-Agent (IBA)

23	Cisplatin (Platino)FDA LinkGeneric 10/2023 - 09/2013
14	IridiumIBA 11/2023 - 01/2017
12	Photosensitizing Agents (Photosensitizers)IBA 10/2023 - 10/2015
11	PlatinumIBA 10/2023 - 08/2014
9	Small Interfering RNA (siRNA)IBA 10/2022 - 03/2012
9	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2022 - 10/2015
7	DNA (Deoxyribonucleic Acid)IBA 10/2022 - 08/2014
7	RutheniumIBA 10/2022 - 01/2017
6	ProdrugsIBA 11/2022 - 09/2020
6	Therapeutic UsesIBA 10/2022 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 04/2023 - 01/2013
5	RheniumIBA 07/2022 - 04/2017
5	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2021 - 08/2014
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 02/2012
5	CyclodextrinsIBA 10/2018 - 01/2014
4	MetalsIBA 10/2023 - 05/2014
4	Coordination ComplexesIBA 04/2023 - 05/2014
3	IronIBA 11/2023 - 10/2020
3	Mitochondrial DNA (mtDNA)IBA 06/2023 - 11/2019
3	LigandsIBA 10/2018 - 08/2017
3	PolyethyleneimineIBA 01/2015 - 01/2013
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 06/2023 - 10/2022
2	InterferonsIBA 06/2023 - 10/2022
2	Nucleic AcidsIBA 04/2023 - 01/2022
2	ZincIBA 01/2023 - 01/2022
2	CytokinesIBA 01/2023 - 10/2022
2	ferroceneIBA 12/2022 - 11/2022
2	RNA (Ribonucleic Acid)IBA 11/2022 - 01/2021
2	Carbonic Anhydrase IXIBA 07/2022 - 01/2022
2	Antineoplastic Agents (Antineoplastics)IBA 07/2022 - 12/2017
2	Oxygen (Dioxygen)IBA 04/2022 - 08/2019
2	lonidamineIBA 09/2020 - 08/2018
2	CaspasesIBA 05/2019 - 01/2016
2	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 12/2018 - 12/2018
2	IntegrinsIBA 10/2018 - 01/2017
2	AdamantaneIBA 10/2018 - 01/2017
2	Silicon Dioxide (Silica)FDA LinkGeneric 01/2018 - 01/2014
2	Folic Acid (Vitamin M)FDA LinkGeneric 01/2015 - 01/2013
2	Amino Acids FDA Link 08/2014 - 04/2011
1	NF-kappa B (NF-kB)IBA 11/2023
1	betulinIBA 11/2023
1	RhodiumIBA 06/2023
1	VaccinesIBA 01/2023
1	Virulence Factors (Pathogenicity Factors)IBA 01/2023
1	LipidsIBA 12/2022
1	Transferrin (beta 2 Transferrin)IBA 12/2022
1	Transferrin Receptors (Transferrin Receptor)IBA 12/2022
1	Chelating AgentsIBA 11/2022
1	Deferasirox FDA Link 11/2022
1	CopperIBA 07/2022
1	Hypoxia-Inducible Factor 1IBA 04/2022
1	flavoneIBA 04/2022
1	EnzymesIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	AntigensIBA 01/2022
1	CurcuminIBA 12/2021
1	Antiviral Agents (Antivirals)IBA 11/2021
1	Peptide Hydrolases (Proteases)FDA Link 11/2021
1	Cysteine Proteases (Cysteine Protease)IBA 11/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2020
1	IonsIBA 09/2020
1	Thymidylate SynthaseIBA 09/2020
1	TegafurIBA 09/2020
1	Antimalarials (Antimalarial Agents)IBA 01/2020
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	ArtesunateIBA 01/2020
1	Schiff Bases (Schiff Base)IBA 07/2019
1	AnionsIBA 03/2019
1	QuercetinIBA 01/2019
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2019

Therapy/Procedure

30	Therapeutics 10/2023 - 03/2012
13	Photochemotherapy (Photodynamic Therapy) 10/2023 - 10/2015
10	Immunotherapy 10/2023 - 07/2022
8	Precision Medicine 07/2019 - 01/2015
6	Drug Therapy (Chemotherapy) 01/2022 - 01/2015
5	Photothermal Therapy 04/2022 - 03/2017